guselkumab vs risankizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT02203032 · Phase 3 · completed
In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.
Next expected readout: December 2026 · NCT05004727 (registry estimate)
Reported efficacy
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)
Result source: NCT02203032
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT02684370 · Phase 3 · completed
This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.
Next expected readout: April 2028 · NCT04862286 (registry estimate)
Reported efficacy
Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)
Result source: NCT02672852
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | risankizumab |
|---|---|---|
| PASI 75 | 84.1% vs 6.3%+77.8 vs placeboNCT0232521911 other results
| 85.2% vs 85.7%vs UstekinumabNCT0443560019 other results
|
| PASI 90 | 70% vs 2.4%+67.6 vs placeboNCT0220724410 other results
| 75.3% vs 4.9%+70.4 vs placeboNCT0268437022 other results
|
| PASI 100 | 50% vs 0%+50 vs placeboNCT029053313 other results
| 35.9% vs 0%+35.9 vs placeboNCT0268437020 other results
|
| sPGA 0/1 | 85.7% vs 7.1%+78.6 vs placeboNCT014835994 other results
| 87.8% vs 7.8%+80 vs placeboNCT0268437028 other results
|
| DLQI, change | -11.2 vs -2.6−8.6 vs placeboNCT0220724410 other results
| -17 vs -9.7vs FumadermNCT03255382 |
PASI 75
- guselkumab
- 84.1% vs 6.3%+77.8 vs placeboNCT02325219
11 other results
- 89.2% vs 6.3% NCT02325219
- 86.3% vs 68.5% NCT02207244
- 92.7% vs 92.8% NCT03090100
- 89.3% vs 91.6% NCT03090100
- 91.2% vs 73.1% NCT02207231
- 78.6% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 75.6% vs 4.8% NCT01483599
- 43.9% vs 4.8% NCT01483599
- 5.1% vs 22.9% NCT03573323
- risankizumab
- 85.2% vs 85.7%vs UstekinumabNCT04435600
19 other results
- 83.3% vs 85.7% NCT04435600
- 92.3% vs 85.7% NCT04435600
- 86.7% vs 85.7% NCT04435600
- 88.7% vs 8% NCT02672852
- 90.8% vs 6.1% NCT02684357
- 90.7% vs 71.7% NCT02694523
- 86.8% vs 70% NCT02684370
- 88.8% vs 69.7% NCT02684357
- 93.3% vs 26.7% NCT03255382
- 86.7% vs 20% NCT03255382
- 75% vs 8.3% NCT03255382
- 13.3% vs 3.3% NCT03255382
- 94.5% vs 8.6% NCT03000075
- 89.7% vs 8.6% NCT03000075
- 90.5% vs 77.5% NCT02054481
- 97.6% vs 77.5% NCT02054481
- 67.4% vs 77.5% NCT02054481
- 84.7% vs 18.8% NCT04908475
- 94% vs 77.5% NCT02054481
PASI 90
- guselkumab
- 70% vs 2.4%+67.6 vs placeboNCT02207244
10 other results
- 73.3% vs 2.9% NCT02207231
- 69.8% vs 0% NCT02325219
- 70.8% vs 0% NCT02325219
- 75.8% vs 0% NCT02905331
- 70% vs 46.8% NCT02207244
- 78.5% vs 79.6% NCT03090100
- 69.1% vs 76.1% NCT03090100
- 73.3% vs 49.7% NCT02207231
- 35.9% vs 58.5% NCT03573323
- 7.9% vs 21% NCT03573323
- risankizumab
- 75.3% vs 4.9%+70.4 vs placeboNCT02684370
22 other results
- 73.2% vs 2% NCT02672852
- 74.8% vs 2% NCT02684357
- 62.9% vs 3.8% NCT03875482
- 72.4% vs 47.4% NCT02694523
- 73.8% vs 65.6% NCT03478787
- 75.3% vs 42% NCT02684370
- 74.8% vs 47.5% NCT02684357
- 64.8% vs 60.7% NCT04435600
- 76.7% vs 11.7% NCT03255382
- 61.7% vs 5% NCT03255382
- 38.3% vs 1.7% NCT03255382
- 1.7% vs 0% NCT03255382
- 83.3% vs 60.7% NCT04435600
- 84.6% vs 60.7% NCT04435600
- 76.7% vs 60.7% NCT04435600
- 74.5% vs 1.7% NCT03000075
- 75.9% vs 1.7% NCT03000075
- 81% vs 40% NCT02054481
- 73.2% vs 40% NCT02054481
- 32.6% vs 40% NCT02054481
- 55.9% vs 5.1% NCT04908475
- 77.1% vs 40% NCT02054481
PASI 100
- guselkumab
- 50% vs 0%+50 vs placeboNCT02905331
3 other results
- 24.9% vs 41.3% NCT03573323
- 13.6% vs 29.6% NCT03573323
- 1.4% vs 6.7% NCT03573323
- risankizumab
- 35.9% vs 0%+35.9 vs placeboNCT02684370
20 other results
- 47.2% vs 1% NCT02672852
- 50.7% vs 2% NCT02684357
- 38.1% vs 1.9% NCT03875482
- 35.9% vs 12% NCT02684370
- 50.7% vs 24.2% NCT02684357
- 39.9% vs 23% NCT02694523
- 40.7% vs 17.9% NCT04435600
- 35% vs 1.7% NCT03255382
- 23.3% vs 1.7% NCT03255382
- 5% vs 1.7% NCT03255382
- 0% vs 0% NCT03255382
- 41.7% vs 17.9% NCT04435600
- 53.8% vs 17.9% NCT04435600
- 43.3% vs 17.9% NCT04435600
- 32.7% vs 0% NCT03000075
- 22.4% vs 0% NCT03000075
- 50% vs 17.5% NCT02054481
- 41.5% vs 17.5% NCT02054481
- 14% vs 17.5% NCT02054481
- 45.8% vs 17.5% NCT02054481
sPGA 0/1
- guselkumab
- 85.7% vs 7.1%+78.6 vs placeboNCT01483599
4 other results
- 78.6% vs 7.1% NCT01483599
- 83.3% vs 7.1% NCT01483599
- 61% vs 7.1% NCT01483599
- 34.1% vs 7.1% NCT01483599
- risankizumab
- 87.8% vs 7.8%+80 vs placeboNCT02684370
28 other results
- 83.5% vs 7% NCT02672852
- 83.7% vs 5.1% NCT02684357
- 78.1% vs 9.6% NCT03875482
- 83.7% vs 60.2% NCT02694523
- 79.6% vs 75% NCT04435600
- 68.5% vs 67.9% NCT04435600
- 83.3% vs 75% NCT04435600
- 84.6% vs 75% NCT04435600
- 90% vs 75% NCT04435600
- 83.3% vs 67.9% NCT04435600
- 84.6% vs 67.9% NCT04435600
- 83.3% vs 67.9% NCT04435600
- 32.2% vs 11.5% NCT04713592
- 87.8% vs 63% NCT02684370
- 83.7% vs 61.6% NCT02684357
- 82.2% vs 65% NCT02684370
- 82.3% vs 64.6% NCT02684357
- 91.7% vs 31.7% NCT03255382
- 90% vs 33.3% NCT03255382
- 81.7% vs 15% NCT03255382
- 33.3% vs 3.3% NCT03255382
- 75.4% vs 18.4% NCT04908475
- 92.7% vs 10.3% NCT03000075
- 86.2% vs 10.3% NCT03000075
- 90.5% vs 67.5% NCT02054481
- 90.2% vs 67.5% NCT02054481
- 62.8% vs 67.5% NCT02054481
- 90.4% vs 67.5% NCT02054481
DLQI, change
- guselkumab
- -11.2 vs -2.6−8.6 vs placeboNCT02207244
10 other results
- -11.2 vs -0.6 NCT02207231
- -8.5 vs -0.8 NCT02325219
- -7 vs -0.4 NCT02325219
- -8.3 vs -0.8 NCT02325219
- -7.5 vs -0.4 NCT02325219
- -10.8 vs -2.3 NCT01483599
- -11.1 vs -2.3 NCT01483599
- -11.4 vs -2.3 NCT01483599
- -10.3 vs -2.3 NCT01483599
- -6.2 vs -2.3 NCT01483599
- risankizumab
- -17 vs -9.7vs FumadermNCT03255382
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
19 other shared endpoints and safety
Coverage. guselkumab: 23 of 23 rows · risankizumab: 23 of 23 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab Rows use multiple source trials | risankizumab Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points Maintenance | -18.5% (n=59) vs -9.2% (n=57) Fumaric Acid Esters @ 24wka,b NCT02951533 · Phase 3 · registry result, not featured evidence | -19.8% (n=60) vs -9.8% (n=58) Fumaderm @ 24wka,b NCT03255382 · Phase 3 · registry result, not featured evidence |
| DLQI absolute change · score Maintenance | -15.2 vs -9.4 Fumaric Acid Esters score @ 24wka,b NCT02951533 · Phase 3 · registry result, not featured evidence | -18.8 vs -11.2 Fumaderm score @ 24wka,b NCT03255382 · Phase 3 · registry result, not featured evidence |
| DLQI 0/1 responder rate · % of participants Induction | 68.3% (n=60) vs 6.6% (n=61) placebo @ 16wk100 mgc,a,b NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose64.1% (n=64) vs 6.6% (n=61) placebo @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | 65.8% (n=304) vs 7.8% (n=102) placebo @ 16wkc,a,b NCT02684370 · Phase 3 show 1 more dose65.8% (n=304) vs 43% (n=100) Ustekinumab @ 16wk NCT02684370 · Phase 3 |
| DLQI 0/1 responder rate · % of participants Maintenance | 61.7% (n=60) vs 16.9% (n=59) Fumaric Acid Esters @ 24wka,b NCT02951533 · Phase 3 · registry result, not featured evidence | 66.7% (n=60) vs 10% (n=60) Fumaderm @ 24wka,b NCT03255382 · Phase 3 · registry result, not featured evidence |
| DLQI 0/1 responder rate · % of participants No placebo or comparator arm | 76.7% (n=60) @ 52wk100 mgc,a,b NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose73.4% (n=64) @ 52wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | 47.1% (n=244) @ 52wk*a,b NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 115 Participants as posted |
| NAPSI absolute change · score Induction | -1.5 vs -0.2 placebo score @ 16wk100 mgc,a,b NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose-1.2 vs -0.2 placebo score @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | -13.6 vs -2.2 Fumaderm score @ 16wkc,a,b NCT03255382 · Phase 3 · registry result, not featured evidence show 1 more dose-21.4 vs -4.2 Fumaderm score @ 16wk NCT03255382 · Phase 3 · registry result, not featured evidence |
| PASI percent change · % of baseline Induction | 91.53% (n=61) vs 8.72% (n=16) placebo @ 16wka,b NCT02905331 · Phase 3 3 other source trials88.7% (n=63) vs 0.2% (n=64) placebo @ 16wk100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 88.9% (n=65) vs 0.2% (n=64) placebo @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 93.65% (n=534) vs 93.94% (n=514) Secukinumab @ 16wk100 mg NCT03090100 · Phase 3 · registry result, not featured evidence | -89.36% (n=101) vs -29.39% (n=50) placebo @ 16wka,b NCT03875482 · Phase 3 · registry result, not featured evidence |
| PASI absolute change · score Induction | -23.9 vs -0.5 placebo score @ 16wk100 mgc,a,b NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose-22.6 vs -0.5 placebo score @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | -16.89 vs -9.11 Fumaderm score @ 16wka,b NCT03255382 · Phase 3 · registry result, not featured evidence |
| PASI percent change · % of baseline No placebo or comparator arm | -84.49% (n=77) @ 16wk100 mga,b NCT05272150 · Phase 3 · registry result, not featured evidence 1 other source trial-82.6% (n=218) @ 16wk100 mg NCT06039189 · Phase 3 · registry result, not featured evidence | -89.33% (n=107) @ 16wka,b NCT03875508 · Phase 3 · registry result, not featured evidence |
| PASI 100 responder rate · % of participants Maintenance | 52.3% (n=507) vs 50% (n=520) Ixekizumab @ 24wkd,a,b NCT03573323 · Phase 4 · registry result, not featured evidence 1 other source trial31.7% (n=60) vs 3.4% (n=59) Fumaric Acid Esters @ 24wk NCT02951533 · Phase 3 · registry result, not featured evidence | 50% (n=60) vs 5% (n=60) Fumaderm @ 24wkd,a,b NCT03255382 · Phase 3 · registry result, not featured evidence |
| PASI 100 responder rate · % of participants No placebo or comparator arm | 44.4% (n=880) @ 28wk100 mge,a,b NCT03818035 · Phase 3 · registry result, not featured evidence | 77.8% (n=9) @ 28wk*600 mgc,e,a,b NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted show 1 more dose88.9% (n=9) @ 28wk*300 mg NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted |
| PASI 50 responder rate · % of participants Induction | 9.3% (n=507) vs 27.5% (n=520) Ixekizumab @ 1wkd,a,b,f NCT03573323 · Phase 4 · registry result, not featured evidence | 91.7% (n=12) vs 92.9% (n=28) Ustekinumab @ 16wkc,d,a,b,f NCT04435600 · Phase 3 show 3 more doses90.7% (n=54) vs 92.9% (n=28) Ustekinumab @ 16wk NCT04435600 · Phase 3 100% (n=13) vs 92.9% (n=28) Ustekinumab @ 16wk NCT04435600 · Phase 3 96.7% (n=30) vs 92.9% (n=28) Ustekinumab @ 16wk NCT04435600 · Phase 3 |
| PASI 75 responder rate · % of participants Maintenance | 90% (n=60) vs 27.1% (n=59) Fumaric Acid Esters @ 24wka,b NCT02951533 · Phase 3 · registry result, not featured evidence | 98.3% (n=60) vs 33.3% (n=60) Fumaderm @ 24wka,b NCT03255382 · Phase 3 · registry result, not featured evidence 4 other source trials55.8% (n=43) vs 70% (n=40) Stelara @ 24wk18 mg NCT02054481 · Phase 2 · registry result, not featured evidence 92.9% (n=42) vs 70% (n=40) Stelara @ 24wk180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 92.7% (n=41) vs 70% (n=40) Stelara @ 24wk90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 92.8% (n=83) vs 70% (n=40) Stelara @ 24wk90+180 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants Maintenance | 75.2% (n=496) vs 54.8% (n=248) Adalimumab @ 24wk100 mga,b NCT02207244 · Phase 3 2 other source trials80.2% (n=329) vs 53% (n=334) Adalimumab @ 24wk NCT02207231 · Phase 3 81.7% (n=60) vs 13.6% (n=59) Fumaric Acid Esters @ 24wk NCT02951533 · Phase 3 · registry result, not featured evidence | 83.3% (n=60) vs 10% (n=60) Fumaderm @ 24wka,b NCT03255382 · Phase 3 · registry result, not featured evidence 4 other source trials30.2% (n=43) vs 55% (n=40) Stelara @ 24wk18 mg NCT02054481 · Phase 2 · registry result, not featured evidence 85.7% (n=42) vs 55% (n=40) Stelara @ 24wk180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 65.9% (n=41) vs 55% (n=40) Stelara @ 24wk90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 75.9% (n=83) vs 55% (n=40) Stelara @ 24wk90+180 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants No placebo or comparator arm | 57.1% (n=77) @ 16wk100 mga,b NCT05272150 · Phase 3 · registry result, not featured evidence 1 other source trial52.9% (n=225) @ 16wk100 mg NCT06039189 · Phase 3 · registry result, not featured evidence | 87.5% (n=8) @ 16wka,b NCT04435600 · Phase 3 5 other source trials100% (n=4) @ 16wk150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 60% (n=5) @ 16wk75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 75% (n=4) @ 16wk150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 100% (n=4) @ 16wk75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 66.7% (n=108) @ 16wk NCT03875508 · Phase 3 · registry result, not featured evidence |
| PSSD Symptom absolute change · score Induction | -40.4 vs -8.3 placebo score @ 16wk100 mga,b NCT02207244 · Phase 3 1 other source trial-41.9 vs -3 placebo score @ 16wk NCT02207231 · Phase 3 | -6.402 vs -0.027 placebo score @ 16wka,b NCT02684357 · Phase 3 |
| Scalp IGA responder rate · % of participants Induction | 82.8% (n=58) vs 10.5% (n=57) placebo @ 16wk100 mgc,g,a,b NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose74.1% (n=58) vs 10.5% (n=57) placebo @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | 60.8% (n=51) vs 13% (n=54) placebo @ 16wkg,a,b NCT05969223 · Phase 4 |
| sPGA (0 responder rate · % of participants Induction | 25.2% (n=507) vs 41.9% (n=520) Ixekizumab @ 12wkd,a,b NCT03573323 · Phase 4 · registry result, not featured evidence | 21.7% (n=60) vs 3.3% (n=60) Fumaderm @ 12wkd,a,b NCT03255382 · Phase 3 · registry result, not featured evidence |
| sPGA 0/1 responder rate · % of participants Maintenance | 76.9% (n=39) vs 48.6% (n=37) Adalimumab @ 40wk100 mgc,h,a,b,i NCT01483599 · Phase 2 · registry result, not featured evidence show 4 more doses71.1% (n=38) vs 48.6% (n=37) Adalimumab @ 40wk50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 81.1% (n=37) vs 48.6% (n=37) Adalimumab @ 40wk200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 59.5% (n=37) vs 48.6% (n=37) Adalimumab @ 40wk15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 35.3% (n=34) vs 48.6% (n=37) Adalimumab @ 40wk5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | 81.1% (n=111) vs 7.1% (n=225) placebo @ 104wkh,a,b,i NCT02672852 · Phase 3 |
| Dropout rate | —100 mgj NCT02203032 · Phase 3 show 42 more results3.6%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 1.6%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 9.5% NCT03573323 · Phase 4 · registry result, not featured evidence 13%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 7.6%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 3.1%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 4.8%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | 1.6%Risankizumab (Part A)j NCT02684370 · Phase 3 show 53 more results—Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 1%Risankizumab (Part A1) NCT02672852 · Phase 3 —Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 0%Part 1: Risankizumab NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 —Part 2 Period A: Risankizumab NCT04435600 · Phase 3 —Part 2 Period C: Risankizumab NCT04435600 · Phase 3 —Part 3: Risankizumab NCT04435600 · Phase 3 —Part 4: Risankizumab NCT04435600 · Phase 3 0.7%Risankizumab (Part A) NCT02684357 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 —Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 —Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 2.3%Risankizumab (Part A) NCT02694523 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 1.8%Study-G Risankizumab (Period A) NCT05969223 · Phase 4 —Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 0%Study-S Risankizumab (Period A) NCT05969223 · Phase 4 —Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 26.2%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence 3.4%Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 16% NCT04102007 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 11.1% NCT03875508 · Phase 3 · registry result, not featured evidence 12.4% NCT03875482 · Phase 3 · registry result, not featured evidence 7.9% NCT03478787 · Phase 3 · registry result, not featured evidence 0% NCT03255382 · Phase 3 · registry result, not featured evidence 70%600 mg NCT05283135 · Phase 2 · registry result, not featured evidence 70%300 mg NCT05283135 · Phase 2 · registry result, not featured evidence —180 mg NCT02203851 · Phase 2 · registry result, not featured evidence —90 mg NCT02203851 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 4.8%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 4.9%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 9.3%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100 mgj NCT02203032 · Phase 3 show 42 more results1.8%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 0%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 1.6% NCT03573323 · Phase 4 · registry result, not featured evidence 1.3%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 1.9%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 0%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | 0.3%Risankizumab (Part A)j NCT02684370 · Phase 3 show 53 more results—Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 0.2%Risankizumab (Part A1) NCT02672852 · Phase 3 —Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 —Part 1: Risankizumab NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 —Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 —Part 2 Period A: Risankizumab NCT04435600 · Phase 3 —Part 2 Period C: Risankizumab NCT04435600 · Phase 3 —Part 3: Risankizumab NCT04435600 · Phase 3 —Part 4: Risankizumab NCT04435600 · Phase 3 0%Risankizumab (Part A) NCT02684357 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 —Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 —Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 1%Risankizumab (Part A) NCT02694523 · Phase 3 —Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 —Study-G Risankizumab (Period A) NCT05969223 · Phase 4 —Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 —Study-S Risankizumab (Period A) NCT05969223 · Phase 4 —Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 6.5%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence 1.1%Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 1.6% NCT04102007 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —150 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence —75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 0.9% NCT03875508 · Phase 3 · registry result, not featured evidence 0% NCT03875482 · Phase 3 · registry result, not featured evidence 0.6% NCT03478787 · Phase 3 · registry result, not featured evidence 0% NCT03255382 · Phase 3 · registry result, not featured evidence —600 mg NCT05283135 · Phase 2 · registry result, not featured evidence —300 mg NCT05283135 · Phase 2 · registry result, not featured evidence —180 mg NCT02203851 · Phase 2 · registry result, not featured evidence —90 mg NCT02203851 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence —75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 2.4%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 2.3%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.7%100 mgj NCT02203032 · Phase 3 show 42 more results1.6%100 mg NCT02207244 · Phase 3 2.1%100 mg NCT02207244 · Phase 3 14%100 mg NCT02207244 · Phase 3 2.5%100 mg NCT02207231 · Phase 3 2.4%100 mg NCT02207231 · Phase 3 —Guselkumab NCT02905331 · Phase 3 3.2%Guselkumab (Week 0-16) NCT02905331 · Phase 3 1.6%Guselkumab (Week 16-40) NCT02905331 · Phase 3 3.2% NCT03573323 · Phase 4 · registry result, not featured evidence 3.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 5.3%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence 4.7%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 6.3%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 2.2%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 3.5%100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 4.3%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 0%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence 4%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 9.7%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 9.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 5%Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence 0%Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence 5.5%Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 6.2%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence 5%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | 2.3%Risankizumab (Part A)j NCT02684370 · Phase 3 show 53 more results5.4%Risankizumab/Risankizumab (Part B) NCT02684370 · Phase 3 2%Risankizumab (Part A1) NCT02672852 · Phase 3 11.7%Risankizumab/Risankizumab (Part B; NCT02672852 · Phase 3 0%Part 1: Risankizumab NCT04435600 · Phase 3 10%Part 2 Period A Risankizumab Non-r NCT04435600 · Phase 3 0%Part 2 Period A Risankizumab Respo NCT04435600 · Phase 3 0%Part 2 Period A: Risankizumab NCT04435600 · Phase 3 0%Part 2 Period C: Risankizumab NCT04435600 · Phase 3 0%Part 3: Risankizumab NCT04435600 · Phase 3 0%Part 4: Risankizumab NCT04435600 · Phase 3 2%Risankizumab (Part A) NCT02684357 · Phase 3 4.5%Risankizumab/Risankizumab (Part B) NCT02684357 · Phase 3 5.7%Adalimumab/Rerandomized to Risanki NCT02694523 · Phase 3 10.5%Adalimumab/Risankizumab (Part B) NCT02694523 · Phase 3 3.3%Risankizumab (Part A) NCT02694523 · Phase 3 4.1%Risankizumab/Risankizumab (Part B) NCT02694523 · Phase 3 1.8%Study-G Risankizumab (Period A) NCT05969223 · Phase 4 1.9%Study-G Risankizumab/Risankizumab NCT05969223 · Phase 4 5.9%Study-S Risankizumab (Period A) NCT05969223 · Phase 4 5.9%Study-S Risankizumab/Risankizumab NCT05969223 · Phase 4 0.8%Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence 0%Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 2.9%Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence 6.9%Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 20%150 mg NCT03047395 · Phase 3 · registry result, not featured evidence —Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence 5.7%Risankizumab (Double-blind Period) NCT04713592 · Phase 3 · registry result, not featured evidence —Risankizumab/Risankizumab NCT04713592 · Phase 3 · registry result, not featured evidence 6%Risankizumab/Risankizumab (Open-la NCT04713592 · Phase 3 · registry result, not featured evidence 7% NCT04102007 · Phase 3 · registry result, not featured evidence 25%150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 50%150 mg NCT03022045 · Phase 3 · registry result, not featured evidence 20%75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03022045 · Phase 3 · registry result, not featured evidence 5.6% NCT03875508 · Phase 3 · registry result, not featured evidence 1% NCT03875482 · Phase 3 · registry result, not featured evidence 5.5% NCT03478787 · Phase 3 · registry result, not featured evidence 1.7% NCT03255382 · Phase 3 · registry result, not featured evidence 0%600 mg NCT05283135 · Phase 2 · registry result, not featured evidence 10%300 mg NCT05283135 · Phase 2 · registry result, not featured evidence 8.7%180 mg NCT02203851 · Phase 2 · registry result, not featured evidence 13.8%90 mg NCT02203851 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 3.6%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 1.9%150 mg NCT03000075 · Phase 2 · registry result, not featured evidence —150 mg NCT03000075 · Phase 2 · registry result, not featured evidence 7.4%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 3.4%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 1.8%75 mg NCT03000075 · Phase 2 · registry result, not featured evidence 0%180 mg NCT02054481 · Phase 2 · registry result, not featured evidence 14.6%90 mg NCT02054481 · Phase 2 · registry result, not featured evidence 11.6%18 mg NCT02054481 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 37 more results100 mg nasopharyngitis 7.1% (placebo 6.5%) headache 5.1% (placebo 2.8%) upper respiratory tract infection 3.2% (placebo 4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 3.7% (placebo 6.5%) upper respiratory tract infection 2.5% (placebo 4%) arthralgia 1.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 30% (placebo 6.5%) upper respiratory tract infection 23.5% (placebo 4%) arthralgia 9.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 20.1% (placebo 9.8%) upper respiratory tract infection 9.6% (placebo 5.2%) gastroenteritis 3.4% (placebo 1.1%) NCT02207231 · Phase 3 100 mg nasopharyngitis 9.1% (placebo 9.8%) upper respiratory tract infection 7.6% (placebo 5.2%) headache 4.3% (placebo 4%) NCT02207231 · Phase 3 injection site pain 40.3% (placebo 43.8%) injection site coldness 22.6% (placebo 18.8%) injection site pruritus 12.9% (placebo 12.5%) NCT02905331 · Phase 3 injection site pain 18% (placebo 43.8%) injection site coldness 11.5% (placebo 18.8%) viral upper respiratory tract infection 9.8% (placebo 0%) NCT02905331 · Phase 3 upper respiratory tract infection 8.1% nasopharyngitis 5.3% injection site reaction 1.2% NCT03573323 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 16.9% (placebo 3.8%) nasopharyngitis 11.7% (placebo 3.8%) covid-19 6.5% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 24.7% (placebo 3.8%) covid-19 16% (placebo 0%) arthralgia 7.4% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 15.1% (placebo 2.7%) nasopharyngitis 6.7% (placebo 7.1%) covid-19 4.4% (placebo 0.9%) NCT06039189 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 17.6% headache 5.4% back pain 4.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 18.5% hypertension 5.9% arthralgia 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W covid-19 14.7% nasopharyngitis 12.5% psoriasis 7.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 14.1% covid-19 9.3% headache 5.7% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nasopharyngitis 24.3% headache 9% hypertension 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nail psoriasis 22.2% back pain 11.1% covid-19 11.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 15.4% headache 6% back pain 5.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 12.4% covid-19 8.8% psoriasis 8.8% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 50% (placebo 10.9%) eczema 11.3% (placebo 1.6%) injection site erythema 11.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 12.7% (placebo 10.9%) dental caries 3.2% (placebo 1.6%) upper respiratory tract infection 3.2% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 60.3% (placebo 10.9%) arthralgia 14.3% (placebo 0%) influenza 14.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 21.5% (placebo 10.9%) alopecia 3.1% (placebo 0%) arthralgia 3.1% (placebo 0%) NCT02325219 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.7% headache 15% diarrhoea 11.7% NCT02951533 · Phase 3 · registry result, not featured evidence aspartate aminotransferase increased 2.8% tooth infection 2.8% abdominal discomfort 0% NCT02951533 · Phase 3 · registry result, not featured evidence nasopharyngitis 50.9% bronchitis 9.1% alanine aminotransferase increased 5.5% NCT02951533 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 22.1% upper respiratory tract infection 15.5% headache 9% NCT03090100 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 10% (placebo 2.4%) upper respiratory tract infection 7.5% (placebo 2.4%) back pain 5% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 100 mg back pain 4.8% (placebo 0%) headache 4.8% (placebo 2.4%) sinusitis 4.8% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg nasopharyngitis 17.9% (placebo 2.4%) back pain 2.6% (placebo 0%) headache 2.6% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg hypertension 7.1% (placebo 2.4%) fatigue 4.8% (placebo 7.1%) arthralgia 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 13.2% (placebo 2.4%) cough 5.3% (placebo 2.4%) upper respiratory tract infection 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg upper respiratory tract infection 7.3% (placebo 2.4%) cough 4.9% (placebo 2.4%) nasopharyngitis 4.9% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg back pain 2.4% (placebo 0%) nasopharyngitis 2.4% (placebo 2.4%) sinusitis 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg headache 9.8% (placebo 2.4%) nasopharyngitis 9.8% (placebo 2.4%) back pain 2.4% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 15.8% (placebo 2.4%) upper respiratory tract infection 10.5% (placebo 2.4%) arthralgia 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 14.6% (placebo 2.4%) back pain 7.3% (placebo 0%) headache 7.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence | j viral upper respiratory tract infection 6.6% (placebo 5.9%) upper respiratory tract infection 5.6% (placebo 2%) headache 3% (placebo 2%) NCT02684370 · Phase 3 show 48 more resultsviral upper respiratory tract infection 13.5% (placebo 5.9%) upper respiratory tract infection 10.1% (placebo 2%) headache 1.7% (placebo 2%) NCT02684370 · Phase 3 nasopharyngitis 5.2% (placebo 6%) headache 3.4% (placebo 0%) arthralgia 1.7% (placebo 2%) NCT02672852 · Phase 3 nasopharyngitis 20.7% (placebo 6%) upper respiratory tract infection 14.4% (placebo 5%) arthralgia 9% (placebo 2%) NCT02672852 · Phase 3 headache 16.7% (placebo 4.8%) pyrexia 16.7% (placebo 0%) abdominal pain 8.3% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 40% (placebo 9.5%) covid-19 20% (placebo 9.5%) conjunctivitis 10% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 22.7% (placebo 9.5%) headache 18.2% (placebo 4.8%) skin papilloma 13.6% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 18.5% (placebo 9.5%) covid-19 9.3% (placebo 9.5%) headache 5.6% (placebo 4.8%) NCT04435600 · Phase 3 pyrexia 25% (placebo 0%) bacterial vaginosis 12.5% (placebo 0%) chills 12.5% (placebo 0%) NCT04435600 · Phase 3 cough 15.4% (placebo 4.8%) upper respiratory tract infection 15.4% (placebo 4.8%) blood potassium increased 7.7% (placebo 0%) NCT04435600 · Phase 3 nasopharyngitis 31.3% (placebo 9.5%) pyrexia 12.5% (placebo 0%) cough 9.4% (placebo 4.8%) NCT04435600 · Phase 3 upper respiratory tract infection 3.7% (placebo 2%) viral upper respiratory tract infection 3.4% (placebo 2%) influenza 2% (placebo 1%) NCT02684357 · Phase 3 viral upper respiratory tract infection 11.7% (placebo 2%) upper respiratory tract infection 8.2% (placebo 2%) diarrhoea 2.1% (placebo 3.1%) NCT02684357 · Phase 3 viral upper respiratory tract infection 26.4% upper respiratory tract infection 7.5% headache 5.7% NCT02694523 · Phase 3 viral upper respiratory tract infection 23.7% hypertension 7.9% upper respiratory tract infection 7.9% NCT02694523 · Phase 3 viral upper respiratory tract infection 8.6% upper respiratory tract infection 7% headache 4% NCT02694523 · Phase 3 viral upper respiratory tract infection 13.3% upper respiratory tract infection 11.6% hypertension 3.1% NCT02694523 · Phase 3 upper respiratory tract infection 7.3% (placebo 3.7%) covid-19 3.6% (placebo 3.7%) nasopharyngitis 3.6% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 7.4% (placebo 3.7%) covid-19 3.7% (placebo 3.7%) nasopharyngitis 3.7% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 11.8% (placebo 3.7%) covid-19 7.8% (placebo 3.7%) nasopharyngitis 2% (placebo 3.7%) NCT05969223 · Phase 4 upper respiratory tract infection 11.8% (placebo 3.7%) covid-19 7.8% (placebo 3.7%) nasopharyngitis 2% (placebo 3.7%) NCT05969223 · Phase 4 covid-19 11% nasopharyngitis 3.4% headache 2.5% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 12.5% nasopharyngitis 10.4% hypertension 6.3% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 11.8% nasopharyngitis 9.8% upper respiratory tract infection 5.9% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 16.4% nasopharyngitis 9.5% hypertension 5.2% NCT04908475 · Phase 4 · registry result, not featured evidence 150 mg nasopharyngitis 22.1% covid-19 16.6% upper respiratory tract infection 14.4% NCT03047395 · Phase 3 · registry result, not featured evidence covid-19 2.3% (placebo 2.3%) NCT04713592 · Phase 3 · registry result, not featured evidence covid-19 14.3% (placebo 2.3%) NCT04713592 · Phase 3 · registry result, not featured evidence 150 mg viral upper respiratory tract infection 75% otitis media 50% acne 25% NCT03022045 · Phase 3 · registry result, not featured evidence 150 mg dehydration 50% abdominal pain upper 25% acne 25% NCT03022045 · Phase 3 · registry result, not featured evidence 75 mg viral upper respiratory tract infection 60% constipation 20% diarrhoea 20% NCT03022045 · Phase 3 · registry result, not featured evidence 75 mg alanine aminotransferase increased 25% aspartate aminotransferase increased 25% erythema 25% NCT03022045 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% upper respiratory tract infection 5.6% NCT03875508 · Phase 3 · registry result, not featured evidence nasopharyngitis 21.3% upper respiratory tract infection 12.8% arthralgia 5.5% NCT03478787 · Phase 3 · registry result, not featured evidence nasopharyngitis 58.3% headache 8.3% oropharyngeal pain 8.3% NCT03255382 · Phase 3 · registry result, not featured evidence 600 mg upper respiratory infection 50% common cold 30% covid-19 infection 30% NCT05283135 · Phase 2 · registry result, not featured evidence 300 mg upper respiratory infection 20% bleeding internal hemorrhoids 10% bursitis, left elbow 10% NCT05283135 · Phase 2 · registry result, not featured evidence 180 mg upper respiratory tract infection 17.4% dermatitis contact 13% nasopharyngitis 13% NCT02203851 · Phase 2 · registry result, not featured evidence 90 mg nasopharyngitis 18.4% upper respiratory tract infection 12.6% arthralgia 10.3% NCT02203851 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 29.6% (placebo 13.8%) arthralgia 11.1% (placebo 1.7%) oral herpes 7.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 18.2% (placebo 13.8%) arthralgia 3.6% (placebo 1.7%) back pain 1.8% (placebo 1.7%) NCT03000075 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 20.4% (placebo 13.8%) dental caries 7.4% (placebo 1.7%) blood triglycerides increased 5.6% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 29.6% (placebo 13.8%) arthralgia 11.1% (placebo 1.7%) asteatosis 7.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg diabetes mellitus 5.2% (placebo 1.7%) nasopharyngitis 5.2% (placebo 13.8%) back pain 3.4% (placebo 1.7%) NCT03000075 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 21.4% (placebo 13.8%) hepatic function abnormal 5.4% (placebo 0%) influenza 5.4% (placebo 0%) NCT03000075 · Phase 2 · registry result, not featured evidence 180 mg nasopharyngitis 26.2% arthralgia 7.1% headache 7.1% NCT02054481 · Phase 2 · registry result, not featured evidence 90 mg nasopharyngitis 34.1% back pain 9.8% gastroenteritis 9.8% NCT02054481 · Phase 2 · registry result, not featured evidence 18 mg nasopharyngitis 34.9% headache 11.6% folliculitis 7% NCT02054481 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 3 versus Phase 4.
- eTrial phases differ: Phase 2 versus Phase 3.
- fAssessment timepoints differ: 16 weeks versus 1 weeks.
- gTrial phases differ: Phase 4 versus Phase 3.
- hTrial phases differ: Phase 3 versus Phase 2.
- iAssessment timepoints differ: 104 weeks versus 40 weeks.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 13 more results
show 5 more results
show 5 more results
show 1 more result
show 2 more results
show 2 more results
+ 80 further endpoints in the CSV export.
risankizumab
show 3 more results
show 12 more results
show 4 more results
show 9 more results
show 1 more result
+ 28 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)
Result source: NCT05528510
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
Reported efficacy
clinical remission + endoscopic improvement met (met)
Result source: INSPIRE/COMMAND
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | risankizumab |
|---|---|---|
| Clinical remission (induction) | 22.6% vs 7.9%+14.7 vs placeboNCT040334452 other results
| 20.3% vs 6.2%+14.1 vs placeboNCT033981484 other results
|
| Clinical remission (maintenance) | 50% vs 18.9%+31.1 vs placeboNCT040334451 other result
| —Trial running · NCT03398135 |
| Clinical response (induction) | 61.4% vs 27.6%+33.8 vs placeboNCT040334453 other results
| 64.3% vs 35.7%+28.6 vs placeboNCT033981489 other results
|
| Endoscopic improvement (induction) | —Trial running · NCT04033445 | 36.5% vs 12.1%+24.4 vs placeboNCT03398148 |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT04033445 | —Trial running · NCT03398135 |
Clinical remission (induction)
- guselkumab
- 22.6% vs 7.9%+14.7 vs placeboNCT04033445
2 other results
- 21.1% vs 22.2% NCT03662542
- 36.6% vs 22.2% NCT03662542
- risankizumab
- 20.3% vs 6.2%+14.1 vs placeboNCT03398148
4 other results
- 12.4% vs 1.7% NCT03398148
- 9.8% vs 1.7% NCT03398148
- 10.3% vs 1.7% NCT03398148
- 11.5% vs 1.7% NCT03398148
Clinical remission (maintenance)
- guselkumab
- 50% vs 18.9%+31.1 vs placeboNCT04033445
1 other result
- 45.2% vs 18.9% NCT04033445
- risankizumab
- —Trial running · NCT03398135
Clinical response (induction)
- guselkumab
- 61.4% vs 27.6%+33.8 vs placeboNCT04033445
3 other results
- 60.7% vs 27.6% NCT04033445
- 74.6% vs 61.1% NCT03662542
- 83.1% vs 61.1% NCT03662542
- risankizumab
- 64.3% vs 35.7%+28.6 vs placeboNCT03398148
9 other results
- 52.2% vs 30.5% NCT03398148
- 46.2% vs 20% NCT03398148
- 43.5% vs 25% NCT03398148
- 45.9% vs 20% NCT03398148
- 45.9% vs 25% NCT03398148
- 53.4% vs 20% NCT03398148
- 37.9% vs 25% NCT03398148
- 42.6% vs 20% NCT03398148
- 32.8% vs 25% NCT03398148
Endoscopic improvement (induction)
- guselkumab
- —Trial running · NCT04033445
- risankizumab
- 36.5% vs 12.1%+24.4 vs placeboNCT03398148
Corticosteroid-free remission (maintenance)
- guselkumab
- —Trial running · NCT04033445
- risankizumab
- —Trial running · NCT03398135
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 4 of 4 rows · risankizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab | risankizumab |
|---|---|---|
| Dropout rate | 2.8%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0.9%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy | 4.9%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 10.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.8%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Discontinued due to AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.6%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy | 3.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 0%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 3.3%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Serious AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3.8%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6.5%200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 5.6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.5%100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.7%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 2.8%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 3.1%Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy | 6.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results2.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.5%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.9%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.4%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.5%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 5.6%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.6%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 7.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.7%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Most frequent reported AEs | 200 mg IVa anaemia 7.4% (placebo 10.2%) covid-19 5.6% (placebo 4.6%) abdominal pain 3.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results200 mg IV anaemia 6% (placebo 10.2%) upper respiratory tract infection 4.5% (placebo 0%) colitis ulcerative 3% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC colitis ulcerative 3.8% (placebo 2.8%) headache 3.8% (placebo 7.4%) anaemia 2.5% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV anaemia 5% (placebo 10.2%) covid-19 5% (placebo 4.6%) headache 3% (placebo 7.4%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV covid-19 7.6% (placebo 4.6%) colitis ulcerative 4.1% (placebo 2.8%) nasopharyngitis 2.9% (placebo 1.9%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC covid-19 7% (placebo 4.6%) colitis ulcerative 5.4% (placebo 2.8%) anaemia 4.7% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w to 200 mg SC q4w colitis ulcerative 16.1% (placebo 2.8%) covid-19 6.5% (placebo 4.6%) abdominal pain 3.2% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w covid-19 18.4% (placebo 4.6%) colitis ulcerative 16.8% (placebo 2.8%) pyrexia 6.4% (placebo 4.6%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w colitis ulcerative 13.1% (placebo 2.8%) covid-19 10.1% (placebo 4.6%) arthralgia 8% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w to 200 mg SC q4w covid-19 13% (placebo 4.6%) anaemia 8.7% (placebo 10.2%) colitis ulcerative 8.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w covid-19 14.2% (placebo 4.6%) colitis ulcerative 10.2% (placebo 2.8%) arthralgia 6.1% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 400 mg IV anaemia 8.1% (placebo 10.2%) headache 5.4% (placebo 7.4%) arthralgia 3.6% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.5% upper respiratory tract infection 7% neutropenia 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.6% headache 7.1% colitis ulcerative 5.7% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 1.5% colitis ulcerative 1.5% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy | 1200 mg IV colitis ulcerative 4.9% (placebo 8.5%) headache 4.9% (placebo 5.1%) nasopharyngitis 4.9% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 12 more results1200 mg IV covid-19 4.6% (placebo 0%) anaemia 3.2% (placebo 3.4%) headache 2.9% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.9% (placebo 0%) headache 2.9% (placebo 5.1%) anaemia 1.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.7% (placebo 0%) anaemia 2.9% (placebo 3.4%) colitis ulcerative 1.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC nasopharyngitis 8.5% (placebo 6.8%) headache 7% (placebo 5.1%) colitis ulcerative 4.2% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC anaemia 8.5% (placebo 3.4%) covid-19 8.5% (placebo 0%) headache 8.5% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC headache 2.8% (placebo 5.1%) anaemia 1.4% (placebo 3.4%) nasopharyngitis 1.4% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC covid-19 5.6% (placebo 0%) colitis ulcerative 4.2% (placebo 8.5%) anaemia 2.8% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 8.6% (placebo 6.8%) headache 6.9% (placebo 5.1%) anaemia 1.7% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 7% (placebo 6.8%) headache 6.5% (placebo 5.1%) anaemia 3.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 10.8% (placebo 6.8%) anaemia 2.7% (placebo 3.4%) colitis ulcerative 2.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV dry skin 5.6% (placebo 0%) headache 5.6% (placebo 5.1%) nasopharyngitis 5.6% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 600 mg IV nasopharyngitis 8.1% (placebo 6.8%) bronchitis 6.5% (placebo 0%) dry skin 3.2% (placebo 0%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 3 more results
show 4 more results
risankizumab
show 4 more results
show 3 more results
show 9 more results
show 4 more results
show 3 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
+ 8 further endpoints in the CSV export.
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT05347095 (registry estimate)
Reported efficacy
superior to ustekinumab on pooled endoscopic endpoints (met)
Result source: QUASAR/GALAXI
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03104413 · Phase 3 · completed
Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.
Next expected readout: March 2027 · NCT06063967 (registry estimate)
Reported efficacy
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12); US Specific: Percentage of Participants With Endoscopic Response (Week 12); Global Outside of US: Percentage of Participants With Clinical Remission (Week 12); Global Outside of US: Percentage of Participants With Endoscopic Response (Week 12): US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) (met)
Result source: NCT03104413
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | risankizumab |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT03466411 | 42% vs 19.8%+22.2 vs placeboNCT0310441326 other results
|
| Endoscopic response (induction) | —Trial running · NCT03466411 | 28.8% vs 11.2%+17.6 vs placeboNCT0310441310 other results
|
| Clinical remission (maintenance) | —Trial running · NCT03466411 | —Trial running · NCT06063967 |
| Endoscopic response (maintenance) | —Trial running · NCT03466411 | —Trial running · NCT06063967 |
Clinical remission (induction)
- guselkumab
- —Trial running · NCT03466411
- risankizumab
- 42% vs 19.8%+22.2 vs placeboNCT03104413
26 other results
- 28.8% vs 11.2% NCT03104413
- 45.2% vs 24.6% NCT03105128
- 43.5% vs 21.7% NCT03105128
- 40.3% vs 19.8% NCT03104413
- 34.2% vs 11.2% NCT03104413
- 41.6% vs 24.6% NCT03105128
- 41% vs 21.7% NCT03105128
- 34.6% vs 19.3% NCT03104413
- 42% vs 19.8% NCT03104413
- 43.5% vs 21.7% NCT03105128
- 45.2% vs 24.6% NCT03105128
- 20.9% vs 11.2% NCT03104413
- 17.3% vs 8% NCT03104413
- 18.4% vs 10.3% NCT03105128
- 21% vs 9.1% NCT03105128
- 39.8% vs 19.3% NCT03104413
- 40.3% vs 19.8% NCT03104413
- 41% vs 21.7% NCT03105128
- 41.6% vs 24.6% NCT03105128
- 19.4% vs 11.2% NCT03104413
- 18.3% vs 8% NCT03104413
- 18.9% vs 10.3% NCT03105128
- 21.2% vs 9.1% NCT03105128
- 36.6% vs 15.4% NCT02031276
- 28% vs 15.4% NCT02031276
- 19.5% vs 15.4% NCT02031276
Endoscopic response (induction)
- guselkumab
- —Trial running · NCT03466411
- risankizumab
- 28.8% vs 11.2%+17.6 vs placeboNCT03104413
10 other results
- 34.6% vs 19.3% NCT03104413
- 40.3% vs 12% NCT03105128
- 40.3% vs 12% NCT03105128
- 34.2% vs 11.2% NCT03104413
- 39.8% vs 19.3% NCT03104413
- 32.1% vs 12% NCT03105128
- 32.1% vs 12% NCT03105128
- 36.6% vs 12.8% NCT02031276
- 31.7% vs 12.8% NCT02031276
- 26.8% vs 12.8% NCT02031276
Clinical remission (maintenance)
- guselkumab
- —Trial running · NCT03466411
- risankizumab
- —Trial running · NCT06063967
Endoscopic response (maintenance)
- guselkumab
- —Trial running · NCT03466411
- risankizumab
- —Trial running · NCT06063967
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 3 of 4 rows · risankizumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab | risankizumab |
|---|---|---|
| Dropout rate | 12.3%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results2%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 5.4%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 8.6%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 11.5%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 20.5%1200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 12.3%600 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 5.3%200 mg NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 1.9%600 mga NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results—360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 2.9%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence —200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results—200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —1200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —600 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | —600 mga NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results—360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence —200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 8.2%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results4.1%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 12.8%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 9.9%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 8.8%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 6.8%1200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 6.8%600 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 7.9%200 mg NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 4.9%600 mga NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results4.8%360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 4.9%180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 4.4%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 7.1%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 7.2%600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 4.4%360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 4.5%180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 3.8%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 5.3%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 6%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 0%600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence 35.4%180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence 9.8%600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence 10.9%600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence 11.3%180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence 24.4%200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 mg IV q4w followed by 100 mg SC q8w arthralgia 11% (placebo 7%) nasopharyngitis 11% (placebo 9.3%) crohn's disease 8.2% (placebo 11.6%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results200 mg IV q4w followed by 200 mg SC q4w covid-19 14.9% (placebo 0%) headache 10.8% (placebo 9.3%) arthralgia 9.5% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg IV q4w followed by 100 mg SC q8w covid-19 12.2% (placebo 0%) upper respiratory tract infection 10.1% (placebo 4.7%) arthralgia 9.5% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg IV q4w followed by 200 mg SC q4w covid-19 20.5% (placebo 0%) upper respiratory tract infection 8.6% (placebo 4.7%) arthralgia 7.3% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg IV q4w followed by 100 mg SC q8w covid-19 18.2% (placebo 0%) upper respiratory tract infection 9.5% (placebo 4.7%) crohn's disease 6.8% (placebo 11.6%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 1200 mg IV q4w followed by 200 mg SC q4w nasopharyngitis 11% (placebo 9.3%) headache 9.6% (placebo 9.3%) arthralgia 5.5% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 600 mg IV q4w followed by 200 mg SC q4w headache 13.7% (placebo 9.3%) nasopharyngitis 12.3% (placebo 9.3%) anaemia 8.2% (placebo 2.3%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg pyrexia 39.5% headache 15.8% nasopharyngitis 10.5% NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 600 mga headache 5.3% (placebo 5.3%) arthralgia 3.9% (placebo 3.9%) nasopharyngitis 3.9% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results360 mg arthralgia 2.4% (placebo 3.9%) headache 2.4% (placebo 5.3%) nausea 2.4% (placebo 4.8%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 180 mg arthralgia 4.9% (placebo 3.9%) crohn's disease 2.4% (placebo 6.3%) headache 2.4% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 1200 mg headache 4.9% (placebo 5.3%) arthralgia 4.4% (placebo 3.9%) nasopharyngitis 3.9% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 1200 mg headache 7.1% (placebo 5.3%) nausea 7.1% (placebo 4.8%) crohn's disease 4.8% (placebo 6.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 600mg IV headache 6.4% (placebo 4.3%) nasopharyngitis 5.9% (placebo 2.7%) nausea 4.3% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 360mg SC headache 4.4% (placebo 4.3%) anaemia 2.9% (placebo 2.7%) crohn's disease 1.5% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 180mg SC crohn's disease 3% (placebo 5.4%) headache 1.5% (placebo 4.3%) nasopharyngitis 1.5% (placebo 2.7%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV nasopharyngitis 5.9% (placebo 2.7%) headache 5.4% (placebo 4.3%) nausea 3.5% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV headache 6.6% (placebo 4.3%) anaemia 5.3% (placebo 2.7%) nausea 3.9% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV headache 3% (placebo 4.3%) anaemia 1.5% (placebo 2.7%) nasopharyngitis 1.5% (placebo 2.7%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 600 mg IV abdominal pain upper 25% ear pain 25% haematochezia 25% NCT02513459 · Phase 2 · registry result, not featured evidence 180 mg SC nasopharyngitis 30.8% gastroenteritis 23.1% fatigue 20% NCT02513459 · Phase 2 · registry result, not featured evidence 600 mg IV arthralgia 19.5% (placebo 10.3%) headache 12.2% (placebo 12.8%) abdominal pain 9.8% (placebo 12.8%) NCT02031276 · Phase 2 · registry result, not featured evidence 600 mg IV abdominal pain 10.9% (placebo 12.8%) nasopharyngitis 7.9% (placebo 7.7%) arthralgia 6.9% (placebo 10.3%) NCT02031276 · Phase 2 · registry result, not featured evidence 180 mg SC nasopharyngitis 14.5% (placebo 7.7%) arthralgia 9.7% (placebo 10.3%) headache 9.7% (placebo 12.8%) NCT02031276 · Phase 2 · registry result, not featured evidence 200 mg IV nausea 22% (placebo 10.3%) abdominal pain 14.6% (placebo 12.8%) arthralgia 14.6% (placebo 10.3%) NCT02031276 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 2 more results
show 3 more results
show 3 more results
show 11 more results
show 11 more results
show 11 more results
risankizumab
show 26 more results
show 10 more results
show 15 more results
show 3 more results
show 3 more results
show 3 more results
show 10 more results
show 15 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
+ 32 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT03162796 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial, and both guselkumab doses beat placebo on the week-24 ACR20 joint response (p<0.001). The protocol's sample-size calculation called for 360 patients, and 383 were enrolled.
Next expected readout: April 2027 · NCT04929210 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants (met)
Result source: NCT04882098
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03675308 · Phase 3 · active, not recruiting
Randomized, double-blind, placebo-controlled trial in 964 patients with a validated clinical response measure (ACR20 at week 24) as the primary endpoint, which risankizumab met (57.3% vs 33.5%, p<0.001). The protocol and the published report state a power calculation for the ACR20 endpoint based on about 880 patients, and 964 were randomized.
Next expected readout: August 2029 · NCT06865105 (registry estimate)
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) (met)
Result source: NCT03675308
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | risankizumab |
|---|---|---|
| ACR20 | 52% vs 22.2%+29.8 vs placeboNCT0316279627 other results
| 61.9% vs 35.7%+26.2 vs placeboNCT027191715 other results
|
| ACR50 | 22.8% vs 12.7%+10.1 vs placeboNCT0316279626 other results
| 23.8% vs 11.9%+11.9 vs placeboNCT027191715 other results
|
| PASI 75 | 80% vs 84.8%−4.8 vs placeboNCT031627968 other results
| —Not posted · NCT06624228 |
| Minimal disease activity | 33.9% vs 31.1%+2.8 vs placeboNCT031627969 other results
| —Not posted · NCT06624228 |
| HAQ-DI, change | -0.3 vs -0.1−0.1 vs placeboNCT0316279630 other results
| -0.2 vs -0.1−0.1 vs placeboNCT027191715 other results
|
ACR20
- guselkumab
- 52% vs 22.2%+29.8 vs placeboNCT03162796
27 other results
- 59.4% vs 22.2% NCT03162796
- 52% vs 25.4% NCT03162796
- 60.2% vs 25.4% NCT03162796
- 52% vs 25.4% NCT03162796
- 60.2% vs 25.4% NCT03162796
- 43.3% vs 27% NCT03162796
- 53.1% vs 27% NCT03162796
- 51.2% vs 30.2% NCT03162796
- 62.5% vs 30.2% NCT03162796
- 36.2% vs 18.3% NCT03162796
- 39.1% vs 18.3% NCT03162796
- 52% vs 22.2% NCT03162796
- 59.4% vs 22.2% NCT03162796
- 54.5% vs 27.2% NCT03162796
- 60.8% vs 27.2% NCT03162796
- 15.7% vs 7.9% NCT03162796
- 20.3% vs 7.9% NCT03162796
- 68.9% vs 50% NCT03162796
- 74.4% vs 50% NCT03162796
- 70.3% vs 56.9% NCT03162796
- 71.1% vs 56.9% NCT03162796
- 73.5% vs 61.7% NCT03162796
- 72% vs 61.7% NCT03162796
- 67.9% vs 68.3% NCT03162796
- 75.8% vs 68.3% NCT03162796
- 58% vs 18.4% NCT02319759
- 60% vs 16.3% NCT02319759
- risankizumab
- 61.9% vs 35.7%+26.2 vs placeboNCT02719171
5 other results
- 59% vs 35.7% NCT02719171
- 60.5% vs 35.7% NCT02719171
- 57.1% vs 35.7% NCT02719171
- 59.5% vs 35.7% NCT02719171
- 65% vs 35.7% NCT02719171
ACR50
- guselkumab
- 22.8% vs 12.7%+10.1 vs placeboNCT03162796
26 other results
- 26.6% vs 12.7% NCT03162796
- 22.8% vs 12.7% NCT03162796
- 26.6% vs 12.7% NCT03162796
- 20.5% vs 10.3% NCT03162796
- 24.2% vs 10.3% NCT03162796
- 29.1% vs 13.5% NCT03162796
- 37.5% vs 13.5% NCT03162796
- 29.9% vs 8.7% NCT03162796
- 35.9% vs 8.7% NCT03162796
- 7.9% vs 7.9% NCT03162796
- 10.9% vs 7.9% NCT03162796
- 29.9% vs 8.7% NCT03162796
- 35.9% vs 8.7% NCT03162796
- 30.9% vs 9.6% NCT03162796
- 36.8% vs 9.6% NCT03162796
- 1.6% vs 2.4% NCT03162796
- 3.1% vs 2.4% NCT03162796
- 42.6% vs 21.4% NCT03162796
- 39.2% vs 21.4% NCT03162796
- 47.1% vs 32.7% NCT03162796
- 44.6% vs 32.7% NCT03162796
- 51.3% vs 30.8% NCT03162796
- 46% vs 30.8% NCT03162796
- 43.4% vs 36.5% NCT03162796
- 55.6% vs 36.5% NCT03162796
- 34% vs 10.2% NCT02319759
- risankizumab
- 23.8% vs 11.9%+11.9 vs placeboNCT02719171
5 other results
- 38.5% vs 11.9% NCT02719171
- 30.9% vs 11.9% NCT02719171
- 23.8% vs 11.9% NCT02719171
- 23.8% vs 11.9% NCT02719171
- 25% vs 11.9% NCT02719171
PASI 75
- guselkumab
- 80% vs 84.8%−4.8 vs placeboNCT03162796
8 other results
- 94.3% vs 84.8% NCT03162796
- 75.6% vs 14.1% NCT03162796
- 86.5% vs 14.1% NCT03162796
- 76.5% vs 20.6% NCT03162796
- 87.5% vs 20.6% NCT03162796
- 63.4% vs 20.5% NCT03162796
- 73% vs 20.5% NCT03162796
- 78.6% vs 12.5% NCT02319759
- risankizumab
- —Not posted · NCT06624228
Minimal disease activity
- guselkumab
- 33.9% vs 31.1%+2.8 vs placeboNCT03162796
9 other results
- 40.3% vs 31.1% NCT03162796
- 22.8% vs 11.1% NCT03162796
- 30.5% vs 11.1% NCT03162796
- 23.6% vs 12.3% NCT03162796
- 31.2% vs 12.3% NCT03162796
- 15.7% vs 7.1% NCT03162796
- 18% vs 7.1% NCT03162796
- 23% vs 2% NCT02319759
- 18% vs 0% NCT02319759
- risankizumab
- —Not posted · NCT06624228
HAQ-DI, change
- guselkumab
- -0.3 vs -0.1−0.1 vs placeboNCT03162796
30 other results
- -0.3 vs -0.1 NCT03162796
- -0.2 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.2 vs -0.1 NCT03162796
- -0.2 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.1 vs 0.0 NCT03162796
- -0.1 vs 0.0 NCT03162796
- -0.4 vs -0.2 NCT03162796
- -0.4 vs -0.2 NCT03162796
- -0.4 vs -0.3 NCT03162796
- -0.4 vs -0.3 NCT03162796
- -0.5 vs -0.4 NCT03162796
- -0.4 vs -0.4 NCT03162796
- -0.4 vs -0.4 NCT03162796
- -0.5 vs -0.4 NCT03162796
- -0.4 vs -0.1 NCT02319759
- -0.3 vs -0.1 NCT02319759
- -0.4 vs -0.1 NCT02319759
- -0.4 vs -0.1 NCT02319759
- -0.3 vs -0.1 NCT02319759
- -0.4 vs -0.1 NCT02319759
- -0.2 vs -0.0 NCT02319759
- risankizumab
- -0.2 vs -0.1−0.1 vs placeboNCT02719171
5 other results
- -0.2 vs -0.1 NCT02719171
- -0.2 vs -0.1 NCT02719171
- -0.2 vs -0.1 NCT02719171
- -0.2 vs -0.1 NCT02719171
- -0.1 vs -0.1 NCT02719171
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. guselkumab: 14 of 14 rows · risankizumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab Rows use multiple source trials | risankizumab Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 75.9% (n=234) @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses77% (n=227) @ 52wk100 mg q4w NCT03158285 · Phase 3 79.1% (n=240) @ 52wk100 mg q8w NCT03158285 · Phase 3 78.9% (n=232) @ 52wk100 mg q8w NCT03158285 · Phase 3 | 75.2% (n=101) @ 52wkb,c,d NCT02986373 · Phase 2 · registry result, not featured evidence |
| ACR70 responder rate · % of participants | 7.8% (n=128) vs 5.6% (n=126) placebo @ 16wk100 mg q4wa,b,c,d NCT03162796 · Phase 3 show 1 more dose7.9% (n=127) vs 5.6% (n=126) placebo @ 16wk100 mg q8w NCT03162796 · Phase 3 | 25.6% (n=39) vs 0% (n=42) placebo @ 16wk150 mg weeks 0 and 12a,b,c,d NCT02719171 · Phase 2 · registry result, not featured evidence show 5 more doses7.1% (n=42) vs 0% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 16% (n=81) vs 0% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 14.3% (n=42) vs 0% (n=42) placebo @ 16wk150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 10.7% (n=84) vs 0% (n=42) placebo @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 15% (n=20) vs 0% (n=42) placebo @ 16wk75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.5082 score @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses-0.5111 score @ 52wk100 mg q4w NCT03158285 · Phase 3 -0.4824 score @ 52wk100 mg q8w NCT03158285 · Phase 3 -0.4801 score @ 52wk100 mg q8w NCT03158285 · Phase 3 | -0.318 score @ 52wkb,c,d NCT02986373 · Phase 2 · registry result, not featured evidence |
| Modified Sharp absolute change · score No placebo or comparator arm | 0.29 score @ 24wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 1 more dose0.52 score @ 24wk100 mg q8w NCT03158285 · Phase 3 | 0.12 score @ 24wka,b,c,d NCT02986373 · Phase 2 · registry result, not featured evidence show 1 more dose0.38 score @ 24wk NCT02986373 · Phase 2 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants | 52.8% (n=89) vs 10.3% (n=78) placebo @ 16wk100 mg q4wa,b,c,d NCT03162796 · Phase 3 show 1 more dose45.1% (n=82) vs 10.3% (n=78) placebo @ 16wk100 mg q8w NCT03162796 · Phase 3 | 52.2% (n=23) vs 9.5% (n=21) placebo @ 16wk150 mg weeks 0 and 12a,b,c,d NCT02719171 · Phase 2 · registry result, not featured evidence show 5 more doses66.7% (n=18) vs 9.5% (n=21) placebo @ 16wk150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 58.5% (n=41) vs 9.5% (n=21) placebo @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 58.3% (n=12) vs 9.5% (n=21) placebo @ 16wk150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 63.3% (n=30) vs 9.5% (n=21) placebo @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 55.6% (n=9) vs 9.5% (n=21) placebo @ 16wk75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| SF-36 MCS absolute change · score | 3.04 vs 2.25 placebo score @ 16wk100 mg q4wa,b,c,d NCT03162796 · Phase 3 show 1 more dose2.61 vs 2.25 placebo score @ 16wk100 mg q8w NCT03162796 · Phase 3 | 2.84 vs 0.48 placebo score @ 16wk150 mg weeks 0 and 12a,b,c,d NCT02719171 · Phase 2 · registry result, not featured evidence show 5 more doses2.26 vs 0.48 placebo score @ 16wk150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 2.29 vs 0.48 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence -0.36 vs 0.48 placebo score @ 16wk150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 1.31 vs 0.48 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence -1.08 vs 0.48 placebo score @ 16wk75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| SF-36 MCS absolute change · score No placebo or comparator arm | 4.076 score @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses4.127 score @ 52wk100 mg q4w NCT03158285 · Phase 3 4.465 score @ 52wk100 mg q8w NCT03158285 · Phase 3 4.54 score @ 52wk100 mg q8w NCT03158285 · Phase 3 | 4.33 score @ 52wkb,c,d NCT02986373 · Phase 2 · registry result, not featured evidence |
| SF-36 PCS absolute change · score | 6.72 vs 2.5 placebo score @ 16wk100 mg q4wa,b,c,d NCT03162796 · Phase 3 show 1 more dose5.26 vs 2.5 placebo score @ 16wk100 mg q8w NCT03162796 · Phase 3 | 3.1 vs 1.93 placebo score @ 16wk150 mg weeks 0 and 12a,b,c,d NCT02719171 · Phase 2 · registry result, not featured evidence show 5 more doses3.5 vs 1.93 placebo score @ 16wk150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 3.32 vs 1.93 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 3.87 vs 1.93 placebo score @ 16wk150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 3.8 vs 1.93 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 7.42 vs 1.93 placebo score @ 16wk75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| SF-36 PCS absolute change · score No placebo or comparator arm | 8.96 score @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses9.023 score @ 52wk100 mg q4w NCT03158285 · Phase 3 9.511 score @ 52wk100 mg q8w NCT03158285 · Phase 3 9.438 score @ 52wk100 mg q8w NCT03158285 · Phase 3 | 4.47 score @ 52wkb,c,d NCT02986373 · Phase 2 · registry result, not featured evidence |
| SPARCC Enthesitis Index absolute change · score | -4 vs -3.9 placebo score @ 52wk100 mg q4wa,b,c,d,e NCT03162796 · Phase 3 show 1 more dose-4.1 vs -3.9 placebo score @ 52wk100 mg q8w NCT03162796 · Phase 3 | -1.8 vs -1.1 placebo score @ 16wk150 mg weeks 0 and 12a,b,c,d,e NCT02719171 · Phase 2 · registry result, not featured evidence show 5 more doses-2.4 vs -1.1 placebo score @ 16wk150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence -2.1 vs -1.1 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence -1.4 vs -1.1 placebo score @ 16wk150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence -1.7 vs -1.1 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence -3.7 vs -1.1 placebo score @ 16wk75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 2.3%100 mg q4wf NCT03162796 · Phase 3 show 13 more results—100 mg q4w NCT03162796 · Phase 3 —100 mg q4w NCT03162796 · Phase 3 3.1%100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 3.7%100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 3.2%100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 1%Guselkumab (Week 0 to Week 56) NCT02319759 · Phase 2 · registry result, not featured evidence —Placebo to Guselkumab (Week 24 to NCT02319759 · Phase 2 · registry result, not featured evidence | —150 mgf NCT03671148 · Phase 3 show 5 more results26.9% NCT02986373 · Phase 2 · registry result, not featured evidence 5.1%150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 7.1%150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 9.5%150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 10%75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.8%100 mg q4wf NCT03162796 · Phase 3 show 13 more results—100 mg q4w NCT03162796 · Phase 3 —100 mg q4w NCT03162796 · Phase 3 2.4%100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 2.4%100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 0.8%100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 —Guselkumab (Week 0 to Week 56) NCT02319759 · Phase 2 · registry result, not featured evidence —Placebo to Guselkumab (Week 24 to NCT02319759 · Phase 2 · registry result, not featured evidence | —150 mgf NCT03671148 · Phase 3 show 5 more results2.8% NCT02986373 · Phase 2 · registry result, not featured evidence 0%150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 0%150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 4.8%150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 10%75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —100 mg q4wf NCT03162796 · Phase 3 show 13 more results0%100 mg q4w NCT03162796 · Phase 3 3.1%100 mg q4w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 3.1%100 mg q8w NCT03162796 · Phase 3 6.3%100 mg q8w NCT03162796 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 3.3%100 mg q4w NCT03158285 · Phase 3 9%100 mg q4w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 1.2%100 mg q8w NCT03158285 · Phase 3 8.9%100 mg q8w NCT03158285 · Phase 3 6%Guselkumab (Week 0 to Week 56) NCT02319759 · Phase 2 · registry result, not featured evidence 0%Placebo to Guselkumab (Week 24 to NCT02319759 · Phase 2 · registry result, not featured evidence | 4%150 mgf NCT03671148 · Phase 3 show 5 more results3.4% NCT02986373 · Phase 2 · registry result, not featured evidence 5.1%150 mg weeks 0 and 12 NCT02719171 · Phase 2 · registry result, not featured evidence 0%150 mg weeks 0, 4, and 16 NCT02719171 · Phase 2 · registry result, not featured evidence 7.1%150 mg every 4 weeks NCT02719171 · Phase 2 · registry result, not featured evidence 15%75 mg week 0 NCT02719171 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mg q4wf upper respiratory tract infection 8.6% (placebo 6.3%) nasopharyngitis 5.5% (placebo 6.3%) enthesopathy 4.7% (placebo 4.8%) NCT03162796 · Phase 3 show 9 more results100 mg q4w upper respiratory tract infection 12.5% (placebo 6.3%) nasopharyngitis 10.9% (placebo 6.3%) alanine aminotransferase increased 7% (placebo 2.4%) NCT03162796 · Phase 3 100 mg q8w nasopharyngitis 12.6% (placebo 6.3%) aspartate aminotransferase increased 7.1% (placebo 2.4%) alanine aminotransferase increased 6.3% (placebo 2.4%) NCT03162796 · Phase 3 100 mg q8w nasopharyngitis 16.5% (placebo 6.3%) aspartate aminotransferase increased 8.7% (placebo 2.4%) upper respiratory tract infection 7.9% (placebo 6.3%) NCT03162796 · Phase 3 100 mg q4w alanine aminotransferase increased 9% (placebo 4.5%) upper respiratory tract infection 5.3% (placebo 3.3%) nasopharyngitis 4.9% (placebo 3.7%) NCT03158285 · Phase 3 100 mg q4w alanine aminotransferase increased 12.7% (placebo 4.5%) aspartate aminotransferase increased 9.4% (placebo 2.4%) nasopharyngitis 8.6% (placebo 3.7%) NCT03158285 · Phase 3 100 mg q8w alanine aminotransferase increased 6% (placebo 4.5%) aspartate aminotransferase increased 5.6% (placebo 2.4%) nasopharyngitis 4% (placebo 3.7%) NCT03158285 · Phase 3 100 mg q8w alanine aminotransferase increased 11.7% (placebo 4.5%) nasopharyngitis 10.1% (placebo 3.7%) upper respiratory tract infection 9.7% (placebo 3.3%) NCT03158285 · Phase 3 nasopharyngitis 10% (placebo 10.2%) leukopenia 5% (placebo 0%) alanine aminotransferase increased 4% (placebo 2%) NCT02319759 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 6.9% (placebo 2%) aspartate aminotransferase increased 6.9% (placebo 0%) leukopenia 3.4% (placebo 0%) NCT02319759 · Phase 2 · registry result, not featured evidence | show 5 more resultsviral upper respiratory tract infection 11% NCT02986373 · Phase 2 · registry result, not featured evidence 150 mg weeks 0 and 12 viral upper respiratory tract infection 23.1% (placebo 4.8%) headache 7.7% (placebo 7.1%) abdominal pain 5.1% (placebo 2.4%) NCT02719171 · Phase 2 · registry result, not featured evidence 150 mg weeks 0, 4, and 16 viral upper respiratory tract infection 11.9% (placebo 4.8%) upper respiratory tract infection 7.1% (placebo 11.9%) back pain 4.8% (placebo 2.4%) NCT02719171 · Phase 2 · registry result, not featured evidence 150 mg every 4 weeks viral upper respiratory tract infection 16.7% (placebo 4.8%) cough 7.1% (placebo 4.8%) fatigue 7.1% (placebo 0%) NCT02719171 · Phase 2 · registry result, not featured evidence 75 mg week 0 viral upper respiratory tract infection 20% (placebo 4.8%) abdominal discomfort 5% (placebo 0%) alanine aminotransferase increased 5% (placebo 2.4%) NCT02719171 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 16 weeks versus 52 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 5 more results
show 23 more results
show 17 more results
show 9 more results
show 17 more results
show 17 more results
show 27 more results
show 21 more results
show 21 more results
show 21 more results
show 7 more results
show 11 more results
+ 78 further endpoints in the CSV export.
risankizumab
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · risankizumab's landscape